# Arcturus Therapeutics Holdings Inc. (ARCT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.82, market value $450 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Arcturus Therapeutics Holdings Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 15.3×**. Each dollar of revenue is priced at 15.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.6×**. The shares trade at 2.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -16.2%** (5-yr avg -13.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -348.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -80.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -30.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -340.9%**. Return on all capital, debt included, is -340.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -34.4%**. Each dollar of assets produces -34.4% of profit.

## Growth
- **Revenue growth (1 yr): -46.1%** (3-yr -26.4%/yr, 5-yr 53.8%/yr). Revenue fell 46.1% over the last year, against 53.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 20.0%**. Earnings per share rose 20.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.19**. Debt is 0.19 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.9×**. It would take 1.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 6.64** (quick 6.64). Current assets cover the next year's liabilities 6.64 times.
- **Altman Z-score: 6.11**. A Z-score of 6.11 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Arcturus Therapeutics Holdings Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (10 analysts). 10 analysts cover Arcturus Therapeutics Holdings Inc.; the consensus is buy, with an average price target of $20.20 (+28% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -5.6%** (YTD 158.1%, 3-mo 116.7%). The shares are down 5.6% over twelve months including dividends.
- **From 52-week high: -34.5%** (187.6% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 73**. An RSI of 73 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 2.21** (volatility 92%). Beta of 2.21 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARCT · Page: https://foliofundamentals.com/stocks/arct

Not investment advice.